MedTrace Logo

Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19

NCT04371978 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2021-06-02

No results posted yet for this study

Summary

The coronavirus disease 2019 (COVID-19) is an emerging pandemic in 2020 caused by a novel coronavirus named SARS-CoV2. Diabetes confers a significant additional risk for COVID-19 patients. Dipeptidyl peptidase 4 (DPP-4) is a transmembrane glycoprotein expressed ubiquitously in many tissues. In addition to its effect on glucose levels, DPP-4 has various effects on the immune system and several diseases, including lung diseases. This trial aims to assess the safety and efficacy of linagliptin, a DPP-4 inhibitor, in the treatment of COVID-19. The trial will be randomized without blinding, with one are treated by insulin only for glucose balance and the other by insulin and linagliptin. The trial will assess the effects of linagliptin on different measures of COVID-19 recovery.

Conditions

  • COVID 19
  • Coronavirus
  • Diabetes Mellitus, Type 2
  • Diabetes Mellitus
  • Glucose Metabolism Disorders
  • Metabolic Disease
  • Endocrine System Diseases
  • Dipeptidyl-Peptidase IV Inhibitors
  • Linagliptin
  • Severe Acute Respiratory Syndrome Coronavirus 2
  • Sars-CoV2
  • Hypoglycemic Agents
  • Respiratory Tract Diseases
  • Incretins
  • Hormones

Interventions

DRUG

Linagliptin 5 MG

Linagliptin 5 mg PO once daily

Sponsors & Collaborators

  • Rabin Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2021-04-04
Completion
2021-05-04

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04371978 on ClinicalTrials.gov